Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Download White Paper
Filter by Type:
Filter by Topic:
In this white paper we cover key events in lupus history as well as the current ...
10 min. Read
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID19 and its ...
10 min Read.
Pharm-Olam was contracted to execute a non-interventional study with children aged 3 years and younger, who have an Ultra-Rare Disease.
2 min Read.
Pharm-Olam was contracted to assess subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy. The safety of the substance ...
2 min. Read
Pharm-Olam was contracted to manage and recruit four sites for Phase I, first-in-human research of a PD-1 drug treatment for solid tumor ...
A video overview of Pharm-Olam's Rare Disease CRO services.
2 min. Watch
We'll only send you one email a month featuring our best content from the month before.